恩华药业(002262) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 1,178,806,488.43, representing an increase of 18.76% compared to CNY 992,593,188.54 in the same period last year[3] - Net profit attributable to shareholders was CNY 227,429,413.46, up 20.53% from CNY 188,688,696.04 year-on-year[3] - The net cash flow from operating activities reached CNY 364,395,839.44, reflecting a growth of 27.34% compared to CNY 286,170,933.07 in the previous year[3] - Total operating revenue for Q1 2023 reached CNY 1,178,806,488.43, an increase of 18.7% compared to CNY 992,593,188.54 in Q1 2022[18] - Operating profit for the quarter was CNY 261,579,559.01, representing a 24.7% increase from CNY 209,692,665.09 in Q1 2022[19] - Net profit attributable to the parent company was CNY 227,429,413.46, up 20.6% from CNY 188,688,696.04 in the same period last year[19] - Basic earnings per share for Q1 2023 is CNY 0.484, up 10% from CNY 0.44 year-on-year[14] - Earnings per share for the quarter were CNY 0.23, up from CNY 0.19 in the same period last year[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,815,268,549.17, an increase of 5.15% from CNY 6,481,745,574.76 at the end of the previous year[3] - The total assets as of March 31, 2023, amount to CNY 6,815,268,549.17, an increase from CNY 6,481,745,574.76 at the beginning of the year[16] - The total liabilities as of March 31, 2023, are CNY 906,092,526.39, compared to CNY 793,943,159.84 at the beginning of the year[16] - Total liabilities increased to CNY 1,005,339,007.70, up from CNY 896,989,429.48, indicating a rise of 12.1%[19] - The company's total equity attributable to shareholders reached CNY 5,849,678,037.83, compared to CNY 5,622,248,624.37, marking an increase of 4.0%[19] Cash Flow - The company reported a decrease of 107.70% in net increase in cash and cash equivalents, influenced by cash flows from operating, investing, and financing activities[8] - Cash and cash equivalents at the end of Q1 2023 are CNY 1,519,601,953.76, slightly down from CNY 1,532,214,418.85 at the beginning of the year[15] - Cash inflow from financing activities was 25,000,000.00 CNY, unchanged from the previous year[22] - Cash outflow for financing activities was 15,969,215.29 CNY, slightly down from 16,437,185.78 CNY in the previous year[22] - The company reported a decrease in cash and cash equivalents by 14,166,509.61 CNY during the quarter[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,244, with the largest shareholder holding 35.15% of the shares[9] - The company has a significant shareholder structure, with the top 10 shareholders holding a combined 55.58% of the shares[11] Investment Income - Investment income from financial products was CNY 11,360,194.34, indicating a significant increase of 475.22% year-on-year due to higher returns from financial investments[5][7] - The company recorded investment income of CNY 15,867,492.31, significantly higher than CNY 2,758,525.71 in Q1 2022[19] Tax and Expenses - The company experienced a 55.13% increase in income tax expenses, attributed to higher total profits and deferred tax assets[7] - Research and development expenses amounted to CNY 109,676,566.12, an increase of 8.2% from CNY 100,832,530.58 in Q1 2022[18] Future Outlook - The company expects a positive performance outlook for the first half of 2023, with an upward trend in operating results[13] Other Information - The company did not undergo an audit for the first quarter report[23] - The cash flow from operating activities was not detailed in the provided documents[22]